Literature DB >> 8587621

Effect of a low sodium diet on urinary elimination of cystine in cystinuric children.

L M Rodríguez1, F Santos, S Málaga, V Martínez.   

Abstract

Restriction of sodium intake has been shown to decrease urinary elimination of cystine in adult subjects with cystinuria. This simple therapeutic recommendation may be particularly useful in pediatric patients whose compliance with high fluid ingestion and repeated doses of alkali is usually poor. We studied the effect of sodium intake in 5 cystinuric children (3 males) aged 5.9-9.3 years. Urinary excretion of cystine (means +/- SD) was determined at the end of two sequential 1-week periods in which sodium content of diet was modified. Reduction of sodium intake brought about significant decreases in natriuresis (6.0 +/- 2.1 vs. 1.5 +/- 0.5 mEq/kg/day, p < 0.03) and urine cystine concentration (328.0 +/- 190.7 vs. 14.1 +/- 7.4 mg/l, p < 0.02) while urine volume output remained unchanged (58.0 +/- 36.0 vs. 70.3 +/- 33.0 ml/kg/day). These findings confirm that elimination of cystine is highly influenced by sodium intake in cystinuric children and suggest that a low sodium diet may play a key-role in the treatment of pediatric patients with cystinuria.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587621     DOI: 10.1159/000188761

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  14 in total

Review 1.  Cystine growth inhibition through molecular mimicry: a new paradigm for the prevention of crystal diseases.

Authors:  Michael H Lee; Amrik Sahota; Michael D Ward; David S Goldfarb
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

Review 2.  Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.

Authors:  David S Goldfarb
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-14       Impact factor: 8.237

3.  Klebsiella pneumoniae Expressing VIM-1 Metallo-β-Lactamase Is Resensitized to Cefotaxime via Thiol-Mediated Zinc Chelation.

Authors:  Harpa Karadottir; Maarten Coorens; Zhihai Liu; Yang Wang; Birgitta Agerberth; Christian G Giske; Peter Bergman
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

4.  CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update.

Authors:  Marie Dion; Ghada Ankawi; Ben Chew; Ryan Paterson; Nabil Sultan; Patti Hoddinott; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

5.  Early Recognition and Management of Rare Kidney Stone Disorders.

Authors:  Boss Goldstein; David S Goldfarb
Journal:  Urol Nurs       Date:  2017 Mar-Apr

6.  Evaluation and Medical Management of Patients with Cystine Nephrolithiasis: A Consensus Statement.

Authors:  Brian H Eisner; David S Goldfarb; Michelle A Baum; Craig B Langman; Gary C Curhan; Glenn M Preminger; John C Lieske; Gyan Pareek; Kay Thomas; Anna L Zisman; Dimitri Papagiannopoulos; Roger L Sur
Journal:  J Endourol       Date:  2020-04-06       Impact factor: 2.942

Review 7.  Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up.

Authors:  Thomas Knoll; Antonia Zöllner; Gunnar Wendt-Nordahl; Maurice Stephan Michel; Peter Alken
Journal:  Pediatr Nephrol       Date:  2004-11-25       Impact factor: 3.714

Review 8.  Pathophysiology and treatment of cystinuria.

Authors:  Josep Chillarón; Mariona Font-Llitjós; Joana Fort; Antonio Zorzano; David S Goldfarb; Virginia Nunes; Manuel Palacín
Journal:  Nat Rev Nephrol       Date:  2010-06-01       Impact factor: 28.314

9.  Efficacy of captopril therapy in cystinuria lithiasis. A case report.

Authors:  N Printza; F Koukourgianni; A Papathanasiou; P Augoustides-Savvopoulou; F Papachristou
Journal:  Hippokratia       Date:  2007-04       Impact factor: 0.471

Review 10.  Cystinuria-a urologist's perspective.

Authors:  Kay Thomas; Kathie Wong; John Withington; Matthew Bultitude; Angela Doherty
Journal:  Nat Rev Urol       Date:  2014-03-25       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.